New trials activated in June and July
From the Cancer Clinical Trials Office (CCTO)
New trials activated in June and July
- LU209274 P. Stiff Phase I/II Study of dose escalated carfilzomib, busulfan and melphalan with autologous stem cell transplant for the treatment of patients with multiple myeloma
- LU210128 S. Smith An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma (BGB-3111-212)
- LU210202 S. Smith A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1
- LU212057 S. Berg EA8143: A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
- LU208066 J. Clark DREAMseq (Doublet, Randomized Evaluation in AdvancedMelanoma Sequencing) Trial.
- LU211704 M. Harkenrider Phase II Study of Concurrent and Sequential Carboplatin and Paclitaxel with Adjuvant Radiotherapy for High Risk Endometrial Cancer
- LU209642 M. Harkenrider EMBRACE-II: Image guided intensity modulated External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer (EMBRACE-II)
- LU210853 W. Small Short Course Adjuvant Vaginal Cuff Brachytherapy in Early Endometrial Cancer Compared to Standard of Care (SAVE).
- LU206949 P. Stiff A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) KTE-C19-101